Therapies targeting several genes, including EGFR-TKI (13, 22, 23), ALK-TKIs (24), MET-TKIs (25), antiangiogenic therapy (26, 27) and immune-checkpoint inhibitors (21, 28), were tested in patients with PSC, although given the rarity of the tumor type, large scale studies of any particular therapy may never be completed. This evidence concerns the gene ALK and neoplasm.